(ATEA) Achieves a Microsoft Gold Application Development Competency

HORSHAM, Pa., April 7, 2014  — Astea International Inc. (NASDAQ: ATEA), the leader in service management and mobile workforce solutions, today announced it has attained a Gold Application Development competency, demonstrating a “best-in-class” ability and commitment to meet Microsoft Corp. customers’ evolving needs in today’s dynamic business environment and distinguishing itself within the top 1 percent of Microsoft’s partner ecosystem.

To earn a Microsoft gold competency, partners must successfully complete exams (resulting in Microsoft Certified Professionals) to prove their level of technology expertise, and then designate these certified professionals uniquely to one Microsoft competency, ensuring a certain level of staffing capacity. They also must submit customer references that demonstrate successful projects (along with implementing a yearly customer satisfaction study), meet a revenue commitment (for most gold competencies), and pass technology and/or sales assessments.

Whether on-premise or in the cloud, Astea is the only global solution provider that offers all the cornerstones of service lifecycle management: customer management; service management; asset management; forward and reverse logistics management; third party vendor management; and mobile workforce management with enhanced workforce planning, scheduling and optimization. Astea’s solutions are seamlessly orchestrated to share and leverage information throughout the service lifecycle – removing the traditional barriers between the field and back office. With Astea’s solution modularity, companies can introduce one module at a time or deploy a seamless information backbone across the entire service lifecycle continuum.

“Once again, we are extremely pleased to have achieved a Gold Application Development Competency in the Microsoft Partner Network. Achieving this competency demonstrates our expertise and commitment to leveraging today’s technology to deliver solutions that drive proven benefits for our customers,” said John Tobin, President, Astea International. “We are uniquely qualified to meet the mission-critical service transformation challenges and requirements of global organizations. Our differentiated solution suite, domain expertise, and ongoing commitment to innovation continue to have a dramatic impact in helping our customers accelerate revenue growth, improve customer satisfaction, and lower their overall cost of service.”

“By achieving a gold competency, partners have demonstrated the highest, most consistent capability and commitment to the latest Microsoft technology,” said Phil Sorgen, corporate vice president, Worldwide Partner Group at Microsoft Corp. “These partners have a deep expertise that puts them in the top 1 percent of our partner ecosystem, and their proficiency will help customers drive innovative solutions on the latest Microsoft technology.”

Earning the Application Development competency helps partners differentiate themselves as a trusted expert to their customers through development and deployment of commercial or custom applications built using core Microsoft technologies. By gaining access to a comprehensive set of benefits through the Application Development competency, partners can acquire new customers and help them be more productive and profitable through deployment of business applications, advanced web portals or rich client user interfaces that run on premises or in the cloud.

About Astea International
Astea International is a global provider of software solutions that offer all the cornerstones of service lifecycle management, including customer management, service management, asset management, forward and reverse logistics management and mobile workforce management and optimization. Astea’s solutions link processes, people, parts, and data to empower companies and provide the agility they need to achieve sustainable value in less time, and successfully compete in a global economy. Since 1979, Astea has been helping more than 600 companies drive even higher levels of customer satisfaction with faster response times and proactive communication, creating a seamless, consistent and highly personalized experience at every customer relationship touch point.

www.astea.com. Service Smart. Enterprise Proven.

(CUR) To Present Published ALS Trial Phase I Data

ROCKVILLE, Md., April 7, 2014  — Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem’s NSI-566 stem cell trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) will present Phase I data at the Keystone Symposia, “Engineering Cell Fate and Function,” in Olympic Valley, California, on April 9^th https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1272.

Dr. Feldman will take part in a workshop, organized in collaboration with California Institute for Regenerative Medicine (CIRM), called “Clinical Progress for Stem Cell Therapies.” In the workshop, which will run from 2:30-4:30, Dr. Feldman will discuss the results of the Phase I ALS trial, the first in the world to use intraspinal stem cell transplantation.  Dr. Feldman will also provide the first public update on Phase II of the trial, in which 11 patients have already been treated, bringing the total number of patients treated in the trial to 29. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute, Director of Research of the ALS Clinic at the University of Michigan Health System, and an unpaid consultant to Neuralstem.

About Neuralstem

Neuralstem’s patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions.  The company has completed a Phase I safety trial evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD). Additional indications might include traumatic brain injury (TBI), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information:

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2013.

(FLML) Micropump Sodium Oxybate Positive Results First-in-Man Clinical Trial

(IDIX) Promising Clinical Data and Continued Progress in Hepatitis C

• Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437
• Idenix on Track to Initiate All-Oral Pan-Genotypic Phase II Combination Clinical Study of IDX21437 and Samatasvir in mid-2014
• Idenix Initiates Phase I Clinical Trial of Follow-on Nucleotide Prodrug, IDX21459
• Idenix to Host Conference Call / Webcast at 8:00 a.m. ET today

CAMBRIDGE, Mass., April 7, 2014  — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced continued progress of the Company’s program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus (HCV) infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log₁₀ IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company’s goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial.

“As more all-oral regimens become available to treat hepatitis C, an increased number of patients will be diagnosed and treated. It will be important to have simple, short duration options for our patients. These early data for IDX21437 support its potential to be part of future treatment combinations.” said Professor Edward Gane, MD, Deputy Director and Hepatologist, New Zealand Liver Transplant Unit, Auckland City Hospital in New Zealand, and a clinical investigator in the IDX21437 proof-of-concept study. “Nucleotide-based treatment combinations are favored because of safety, efficacy, high barrier to resistance and low drug-drug interaction potential and we look forward to seeing further results from studies with IDX21437.”

“We are very pleased with these positive data for IDX21437 and we are excited to have two nucleotide prodrug candidates in the clinic,” said Ron Renaud, Idenix’s President and Chief Executive Officer.  “With the initiation of the phase II study of IDX21437 and samatasvir later this year, we will be one of a few companies with an all-oral, pan-genotypic, nucleotide-based combination approach in the clinic. We believe this regimen has the potential to play a significant role in advancing HCV care for the benefit of patients, physicians and payers.”

IDX21437: Topline 7-Day Phase I/II Clinical Results

In January 2014, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-naïve, genotype (GT) 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. The topline clinical results include:

• IDX21437 was well-tolerated with no observed pattern of adverse events or laboratory abnormalities.
• Treatment with IDX21437 exhibited potent pan-genotypic activity in a dose-dependent manner:

• In GT 1 HCV-infected patients (n=8), the mean maximal viral load reduction was 4.2 log₁₀ IU/mL in the 300 mg arm.

• The mean maximal viral load reduction of 4.3 log₁₀ IU/mL was achieved in GT 2 and 3 HCV-infected patients in the 300 mg arm (n=10).

• More detailed findings are expected to be presented at a future scientific meeting.
• Based on these findings, the 300 mg dose of IDX21437 has been chosen for the anticipated phase II combination study with samatasvir.

IDX21459: Phase I Clinical Program

In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg – 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-naïve, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 – 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.

Additional Nucleotide Candidates

Idenix’s primary efforts in nucleotide development will continue to focus on its lead candidate, IDX21437, and follow-on prodrug candidate, IDX21459, as well as earlier-stage nucleotide prodrugs. An important objective for the discovery program is to identify nucleotides offering distinct resistance profiles that can be combined with one of the Company’s current nucleotide clinical candidates to treat HCV. Idenix also announced today that the Company has elected not to continue its clinical development program for HCV nucleotide prodrug, IDX20963, previously placed on clinical hold by the U.S. Food and Drug Administration (FDA).

CONFERENCE CALL AND WEBCAST INFORMATION

Idenix management will host a conference call at 8:00 a.m. ET today. To access the call, please dial (877) 640-9809 (U.S./Canada) or (914) 495-8528 (International) and enter passcode 26004979. A live webcast will be available through the Investor section of the Idenix website at www.idenix.com under “Events & Presentations”. The archived webcast will be available for two weeks following the call on the Idenix website.

ABOUT IDX21437

IDX21437, Idenix’s lead uridine-based nucleotide prodrug inhibitor, has completed the single-dose and seven-day proof-of-concept portions of a phase I/II clinical trial. Extensive preclinical testing for IDX21437 has demonstrated favorable antiviral activity across genotypes 1-6 and a safety profile which supported advancement into clinical trials. Based on this progress, the Company’s goal is to initiate an Idenix-sponsored combination clinical trial of IDX21437 and samatasvir in mid-2014.

ABOUT SAMATASVIR

Samatasvir is an NS5A inhibitor with low picomolar, pan-genotypic antiviral activity in vitro. To date, samatasvir has been safe and well-tolerated after single and multiple doses of up to 150 mg in healthy volunteers up to 14 days duration, and in HCV-infected patients up to 12 weeks duration. Samatasvir has demonstrated potent pan-genotypic antiviral activity in HCV-infected patients with mean maximal viral load reductions up to approximately 4.0 log₁₀ IU/mL across HCV genotypes 1-4 in a proof-of-concept, three-day monotherapy study.

Under a non-exclusive collaboration with Janssen Pharmaceuticals, Inc., Idenix is evaluating all-oral, direct-acting antiviral HCV combination regimens including samatasvir, simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, and TMC647055/r, a once-daily non-nucleoside polymerase inhibitor boosted with low-dose ritonavir being developed by Janssen. In this program, Idenix is conducting two ongoing phase II 12-week clinical trials, HELIX-1 and HELIX-2.

ABOUT HEPATITIS C

Hepatitis C virus is a common blood-borne pathogen infecting three to four million people worldwide annually. The World Health Organization (WHO) estimates that more than 150 million people worldwide are chronically infected with HCV, representing a nearly 5-fold greater prevalence than human immunodeficiency virus.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the Company’s future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “expect,” “plans,” “anticipates,” “intends,” “will,” and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the Company’s potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of samatasvir, IDX21437, IDX21459 or any other drug candidate; the successful development of novel combinations of direct-acting antivirals for the treatment of HCV; and the likelihood and success of any future clinical trials involving samatasvir, IDX21437, IDX21459 or our other drug candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the Company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; and the Company’s ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management’s expectations are described in greater detail under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the Company files with the SEC.

All forward-looking statements reflect the Company’s estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company’s views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company’s estimates change.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman (617) 995-9807

(KIN) to Present at Needham 13th Annual Healthcare Conference

SAN FRANCISCO, April 4, 2014  — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13^th Annual Healthcare Conference in New York City:

Presentation date: April 9, 2014

Presenting time: 12:10 PM ET

Presentation location: Westin Grand Central Hotel, Ambassador Room

The presentation will be webcast live over the Internet and can be accessed through the Investors/Events section of Kindred Bio’s website at www.kindredbio.com. To access the live webcast, please log on to Kindred Bio’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days following the event.

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company’s lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.

Contact
Denise Bevers
Kindred Bio
denise.bevers@kindredbio.com
(650) 701-7909

(CGIX) Announces Launch of CALR Mutation Analysis Test

• New Test Launch Extends CGI’s Leadership in Genomic Testing for Blood Cancers
• CALR Genetic Mutation Test Will Be A Part of CGI’s Comprehensive Focus on Leukemia

RUTHERFORD, N.J., April 4, 2014  — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, has launched a genetic diagnostic test for detecting mutations in the calreticulin (CALR) gene. This test helps physicians identify patients with certain types of myeloproliferative neoplasms (MPN), which are blood cancers that have the potential to evolve into acute leukemia.  Approximately 3 million patients in the U.S. are currently diagnosed with MPNs. CGI is one of the first laboratories in the U.S. to offer this test under both CLIA and NY-State Approvals.

In addition to having diagnostic value, the CALR mutation analysis also has the potential to provide significant prognostic value. Patients with the CALR mutation are understood to have more favorable disease outcomes (including lower risk of thrombosis) as well as longer overall survival in comparison to patients who possess other biomarkers (such as the JAK2 mutation). Therefore, the results of the test could have implications in predicting a patient’s outlook.

“CALR mutation analysis allows for a more comprehensive diagnosis of patients with myeloproliferative neoplasms,” said Dr. Lan Wang, MD, Medical Director at Cancer Genetics. “This test can help simplify the diagnosis of MPN and may be helpful in stratifying patients according to whether they should receive aggressive or conservative disease management. We see CALR mutation testing becoming one of the routine genomic tests provided to MPN patients.”

Mr. Panna Sharma, CEO of Cancer Genetics added, “The CALR mutation analysis is a valuable addition to our test menu. The availability of this test positions CGI as one of the most comprehensive laboratories in the U.S. for MPN and acute leukemia. In launching this test, we responded quickly to demand from the clinical community, demonstrating our ability to rapidly adapt in a fast-paced, evolving environment.”

Myeloproliferative neoplasms (MPN) are a related group of blood cancers that are characterized by the overproduction of mature blood cells.¹ Recent advances in research have demonstrated that mutations in the CALR gene can serve as an important biomarker in the diagnosis of two subtypes of patients with MPN: Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) ^{2, 3}.  CALR mutations do not appear to occur in patients with JAK2 and MPL mutations, which are other well established biomarkers in leukemia.

The value of Calreticulin (CALR) to serve as a biomarker was demonstrated in two independent studies by leading researchers that were conducted last year and published simultaneously in the New England Journal of Medicine ^{2, 3}. Both studies were also presented as late breaking abstracts at the 55th annual meeting of the American Society of Hematology (ASH).

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com. 

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

References:

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon, France: IARC Press, 2008.

2. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of Calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-90.

3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369:2391-405.

CONTACT: Investor Relations
         Michael Rice
         Life Science Advisors LLC
         646-597-6979

         Media Relations
         RedChip Companies, Inc.
         Paul Kuntz, 800-733-2447, ext. 105
         paul@redchip.com

(EXAS) Prices Public Offering of Common Stock

Exact Sciences Corp. (NASDAQ: EXAS) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public. The net proceeds to Exact from this offering are expected to be approximately $119.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Exact. The offering is expected to close on or about April 9, 2014, subject to the satisfaction of customary closing conditions. Exact has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Exact anticipates using the net proceeds from the offering to fund its efforts to obtain FDA approval of its Cologuard test, to fund Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes.

Jefferies LLC, Goldman, Sachs & Co. and Robert W. Baird & Co. Incorporated are acting as joint book-running managers for the proposed offering. William Blair & Company, L.L.C. and Canaccord Genuity Inc. are acting as co-managers of the offering.

A shelf registration statement relating to the shares was filed with the SEC and is effective, and a preliminary prospectus supplement related to the offering has also been filed. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary and final prospectus supplement may also be obtained from: Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by calling 877-547-6340, or by e-mailing Prospectus_Department@Jefferies.com; or Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, or by calling 866-471-2526, or by emailing prospectus-ny@ny.email.gs.com; or Robert W. Baird & Co. Incorporated, Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, or by calling 800-792-2473, or by e-mailing syndicate@rwbaird.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Exact Sciences

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the anticipated closing of the offering, the sufficiency of our capital resources, expected operating losses, expectations concerning our ability to secure FDA approval of and reimbursement for our Cologuard test, our estimated reimbursement amounts, our estimates of the available market size and our potential penetration, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

(SINO) and PENAVICO Establish Cross-Referral and Collaboration Agreement

NEW YORK, April 4, 2014 /PRNewswire/ — Sino-Global Shipping America, Ltd. (NasdaqCM: SINO) (“Sino-Global” or the “Company”), an international shipping agency and logistic services provider, today announced that it has signed a strategic cooperation agreement (the “Agreement”) with state-owned enterprise, China Ocean Shipping Agency (“PENAVICO”) to jointly develop their shipping agency business both in China and overseas through a cross-referral and collaboration arrangement.

Under the terms of the Agreement, Sino-Global and PENAVICO will leverage each other’s strengths at different ports to explore cross-referral and profit sharing opportunities among existing clients. The Agreement has a one-year term and will automatically renew for another year unless a written notice of termination is given by either party at least 30 days before the end of the term.

“We are thrilled to work with PENAVICO, an industry leader with over 60 years of rich history of providing international shipping agency, freight forwarding and logistics services to customers all over the world,” commented Mr. Lei Cao, Chairman and Chief Executive Officer of Sino-Global. “We believe both parties will benefit from the cross-selling and upselling opportunities that this Agreement is expected to generate.”

About China Ocean Shipping Agency

For over 60 years, China Ocean Shipping Agency (“PENAVICO”) has been a leading international shipping and transportation agency in China. Headquartered in Beijing, PENAVICO has a global service network that includes over 80 port offices and 300 service outlets in China as well as representative offices in the U.S., Europe, Japan, South Korea, Singapore, and Hong Kong. For more information, please visit www.penavico.com.cn.

About Sino-Global Shipping America, Ltd.

Founded in the United States of America (“U.S.”) in 2001, Sino-Global Shipping America, Ltd. is a Virginia corporation with its primary U.S. operations in New York. We provide our customers with comprehensive yet customized shipping agency, shipping and chartering, and inland transportation management services. As a general shipping agent, the Company serves ships coming to and departing from a number of countries and regions, including China, Australia, South Africa, Brazil, Hong Kong, Canada, and the U.S.. For more information, please visit: www.sino-global.com.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in Sino-Global’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Sino-Global undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For more information, please contact:

(ESMC) Receives FDA 510(k) Clearance for the Sonomed Escalon VuPad™

ARDMORE, Pa., April 4, 2014  — Escalon Medical Corp. (Nasdaq: ESMC) today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new tablet-based ultrasound imaging system, the Sonomed Escalon VuPad™.

The VuPad™ combines Sonomed Escalon’s superior UBM and newly enhanced B-scan image quality with an ultra-high-resolution screen that has 25% larger viewing area than other portable ultrasound devices.  Proprietary Enhanced Focus Rendering™ enables capture of both crisp still images and high-resolution video clips that can be reviewed frame-by-frame.  The VuPad™ is also remarkably easy to use, thanks to intuitively designed touch screen controls.

“The new VuPad™ is a revolutionary portable ultrasound device that delivers exceptional image quality in a wide range of ophthalmic applications,” commented Chief Executive Officer, Richard J. DePiano Jr.  “It also demonstrates the Company’s ongoing commitment to developing and delivering new best-in-class solutions to build on our position as a leader in ophthalmic ultrasound for over 30 years.”

The VuPad™ was previewed at the annual meeting of the American Academy of Ophthalmology (AAO) in November 2013 and recently garnered additional attention at the 2014 World Ophthalmic Congress in Tokyo.  The VuPad™ will also be on display at The Exchange 2014, Vision Source’s North American Meeting in Boston, April 9-12, and at the Annual Symposium and Congress of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston, April 25-29.

The Company anticipates immediate shipments of VuPad™ systems as orders are received and manufacturing ramps up to meet demand.  CE marking and clearance by other international regulatory bodies is anticipated in the coming months.

Mr. DePiano added, “We are pleased by the initial indications and the long term opportunity surrounding the VuPad™ and other new products in our pipeline; however, we may experience sales fluctuations as we update our product offering.  In addition, planned increases to research and development expenses as well as increased sales and marketing costs could pressure financial results.”

The VuPad™ offers A-scan, B-scan, and/or UBM modalities in a sleek, tablet-like package.  Key features include portable ergonomic design, elegant user interface, wireless interconnectivity to EMR’s, image management systems, and printers, multi-touch ultra-high-resolution touch screen with pinch zoom functionality, and most notably, outstanding image quality and measurement accuracy.

About Escalon Medical  

Founded in 1987, Escalon Medical Corp. (NASDAQ: ESMC) specializes in the development, marketing and distribution of ophthalmic diagnostic imaging and surgical products branded under the Sonomed Escalon name.  Products include a variety of ophthalmic ultrasound, digital imaging and photography, and image management systems, as well as surgical products including intraocular gases, fiber optic light guides and sources, and other surgical vitreoretinal instruments.  The Company seeks to grow its ophthalmic business by further developing and diversifying its product offering through internal development programs, strategic partnerships, and the acquisition of technology so as to best leverage the Company’s distribution capabilities. The Company has headquarters in Ardmore, Pennsylvania and research and development, manufacturing and distribution operations in Lake Success, New York, New Berlin, Wisconsin and Stoneham, Massachusetts.  For additional information visit www.escalonmed.com and www.sonomedescalon.com

Forward Looking Statements  

This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company’s future prospects. These statements are based on the Company’s current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to: implement its growth and marketing strategies, improve upon its operations, including, the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance; grow our remaining ophthalmic business unit, including expanding its product pipeline, obtaining regulatory and marketing approvals, and commercializing, manufacturing and shipping new products; improve our financial position; implement cost reductions; generate cash; and identify, finance and enter into business relationships and acquisitions.  Other factors include uncertainties and risks related to: new product development, regulatory and marketing approvals, commercialization, manufacturing and market acceptance of new products; marketing acceptance of existing products in new markets; research and development activities, including failure to demonstrate clinical efficacy; delays by regulatory authorities, scientific and technical advances by the Company or third parties; introduction of competitive products; ability to reduce staffing and other costs and retain benefit of prior reductions; third party reimbursement and physician training, and general economic conditions.  Further information about these and other relevant risks and uncertainties may be found in the Company’s report on Form 10- K for year ended June 30, 2013, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

Photo – http://photos.prnewswire.com/prnh/20140404/PH98060

(ATNM) CEO Interviewed for “Small Stocks: Big Money” Airing on Fox Business and Bloomberg

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces the availability of an exclusive interview with its President and CEO, Kaushik J. Dave, Ph.D.

Dr. Dave was interviewed by “The RedChip Money Report: Small Stocks Big Money”™ hosted by Dave Gentry, a leading authority on small-cap stocks. Mr. Gentry is the President and CEO of RedChip Companies, an international small-cap research, investor relations, and media company.

During the interview, Dr. Dave provided an overview of Actinium, its patented alpha-emitter technology, current clinical development pipeline, and the multi-billion dollar market opportunity the Company is pursuing. The full interview is available at:

https://www.youtube.com/watch?v=RPGAuWWY8Sg

The interview will air on Fox Business nationwide on Thursday, April 17, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 19, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Saturday, April 19, 2014 at 3:30 p.m. GMT and Sunday, April 20, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday, April 20, 2014 at 3:30 p.m. HKT.

“The RedChip Money Report: Small Stocks Big Money” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies, and reaches 80 million homes on Fox Business; 139 million homes in more than 50 cities on Bloomberg Europe; and an additional 13.5 million homes in a dozen countries on Bloomberg Asia.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

(MNGA) Expands into Georgia with New Distributor

MagneGas Signs Fuel Distribution Contract with Sidney Lee Welding Supply

TAMPA, Fla., April 3, 2014  — MagneGas Corporation (“MagneGas” or the “Company”) (NASDAQ: MNGA), a technology company that counts among its inventions a proprietary system that converts liquid waste into a hydrogen-based fuel, announced today that Sidney Lee Welding Supply, Inc (“Sidney Lee”) of Hampton Georgia has signed on to distribute MagneGas™ fuel throughout the state.  MagneGas plans to ship the fuel from its headquarters in Florida.

“There has been demand for MagneGas fuel from fabrication facilities to scrap yards throughout the state of Georgia,” stated Terry Vernille, Executive Vice President of Gas Sales for MagneGas.  “We took our time to locate the perfect distributor. With four facilities geographically located to service all of the large industrial areas of Georgia, and plans to grow in the near future while maintaining customer service, we feel Sidney Lee is the right partner for us.”

“Having MagneGas to distribute to current and potential customers will give us an advantage over other gas distributors helping us in our future growth,” stated Steve Lee, Vice President of Sidney Lee. “We were recommended to take on the product by another Distributor that we have worked with for years. After seeing it for ourselves, we knew this would give us an advantage. Acetylene prices continue to rise and this is a great product replacement.”

The MagneGas IR App is now available for free in Apple’s App Store for the iPhone or iPad http://bit.ly/AfLYww and at Google Play http://bit.ly/Km2iyk for Android mobile devices.

To be added to the MagneGas investor email list, please email pcarlson@kcsa.com with MNGA in the subject line.

About Sidney Lee Welding Supply, Inc.

With four locations in Georgia, the Company was founded in 1968 by Sidney Lee with the goal of providing the best products and the highest level of customer service. Sidney Lee Welding Supply provides high quality brand name welding products, maintains a large inventory, a strong base of welding knowledge, and dependable service to support all welding efforts. www.sidneylee.com

About MagneGas Corporation

Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is the producer of MagneGas™, a natural gas alternative and metal working fuel that can be made from certain industrial, municipal, agricultural and military liquid wastes following the receipt of appropriate governmental permits.

The Company’s patented Plasma Arc Flow™ process gasifies liquid waste, creating a clean burning hydrogen based fuel that is essentially interchangeable with natural gas. MagneGas can be used for metal working, cooking, heating, powering bi-fuel automobiles and more. For more information on MagneGas, please visit the Company’s website at www.magnegas.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using new ethylene glycol to produce fuel until proper permits to process used liquid waste have been obtained.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

(AMRS) and BASF Reach Agreement for Strain Engineering Collaboration

EMERYVILLE, Calif., April 3, 2014  — Amyris, Inc. (Nasdaq:AMRS) announced that it is entering into a collaborative research and development agreement with BASF SE (XETRA:BAS). Under the agreement, Amyris will use its strain engineering technology to develop a microorganism capable of producing a target molecule identified by BASF.

“Through this new collaboration, Amyris will seek to develop strains capable of producing a relevant target molecule for BASF, which could help performance and competitiveness with the traditional sources for that molecule. Amyris’s synthetic biology and strain engineering technology platform and BASF’s capabilities and superior market leadership in the chemicals industry are complementary, and, I believe, our two companies can build on this initial effort to lead the way to innovative renewable chemicals produced through industrial biotechnology,” said John Melo, President & CEO of Amyris.

Based on success of the initial development program, the companies expect to collaborate further on a strain development program and consider other joint research and development opportunities. The companies have agreed not to disclose any details of the agreement.

About Amyris

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of molecules — flexible building blocks that can be used in a wide range of products. Amyris’s initial portfolio of commercial products is based on Biofene®, Amyris’s brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and commercialization of Amyris’s production in Brazil. www.amyris.com

Amyris Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the plans for a development program and the results and benefits of the program) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-K filed on April 2, 2014. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

CONTACT: Amyris, Inc.
         Joel Velasco
         (510) 740-7481
         investor@amyris.com

(RGDX) Announces Contracts With Six New Provider Networks

— New Contracts Bring the Total Contracted Membership to More Than 174 Million Members Nationally —

LOS ANGELES, April 3, 2014  — Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, today announced that it has signed agreements with six additional health plans across 10 states bringing the Company’s total national contracted membership to more than 174 million lives.

The new agreements include additional Blue Cross Blue Shield contracts in Arizona, Iowa, South Dakota, Pennsylvania, Delaware, and West Virginia. The Company also signed new agreements with an Independent Physician Association (covering two states) in the North West region and a Commercial Health Plan (covering two states) in the North East region of the United States.

These partnerships mark a further step forward in Response Genetics’ growing managed care contracting program. With these agreements, Response Genetics is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of “Blues” subscribers with direct access to Response Genetics to approximately 23 million. Among Response Genetics’ other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).

In addition to its recently launched proprietary ResponseDX: Tissue of Origin™ diagnostic test, Response Genetics’ molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers. Response Genetics’ menu of genomic assays provides treating physicians actionable information on a patient’s tumor by predicting which course of therapy will work best for that patient. In this way, Response Genetics’ participation with these Blues plans should improve plan members’ access to individually-tailored medicine.

About Response Genetics, Inc.

Response Genetics, Inc. (the “Company”) is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company’s technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company’s principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company’s headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX^® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as “project,” “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973

         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

(CORI) Announces Pricing of Initial Public Offering

MENLO PARK, Calif., April 3, 2014  — Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share.  The shares are scheduled to begin trading on the NASDAQ Stock Market on April 3, 2014 under the symbol “CORI”.  All of the shares of common stock are being offered by Corium.  Corium has also granted the underwriters a 30-day option to purchase up to 975,000 additional shares of common stock at the initial public offering price.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 2, 2014.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made solely by means of a prospectus.  A copy of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2^nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37^th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at syndicate@leerink.com.

Investor and Media Contact:

Karen L. Bergman
BCC Partners
kbergman@bccpartners.com
(650) 575-1509

(WATT) Announces Exercise of Underwriters’ Over-Allotment Option

Energous Corporation (“Energous” or “the Company”) (Nasdaq: WATT), a developer of a disruptive wire-free charging technology, announced that the underwriter for its initial public offering exercised its entire over-allotment option to purchase an additional 600,000 shares of the Company’s common stock. Total gross proceeds of Energous’ initial public offering, including the over-allotment, were $27.6 million.

MDB Capital Group LLC acted as the underwriter for the offering.

Energous sold the securities described above pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Copies of the final prospectus relating to this offering may be obtained from: MDB Capital Group LLC, 401 Wilshire Boulevard, Suite 1020, Santa Monica CA 90401; (310) 526-5000.

About Energous Corporation

Energous Corporation is developing WattUp^TM, a wire-free charging technology that will transform the way people charge and power their electronic devices at home, in the office, in the car and beyond. WattUp is a novel, patent- and trademark-pending solution that delivers intelligent, scalable power via the same radio bands as a Wi-Fi router. WattUp differs from current wire-free charging systems in that it allows users to roam and use their devices while charging. The result is a true wire-free experience that saves users from having to remember to plug in their devices or place them on a mat. Energous will initially license WattUp to the mobile accessory market, with an eye toward expanding to other markets over time. For more information, please visit www.energous.com.

About MDB Capital Group

MDB Capital Group is Wall Street’s only IP-focused investment bank, with over 15 years of experience launching development stage disruptive technology companies into the public markets. MDB maximizes the value of disruptive technology companies by positioning them to attract growth capital, strengthening their patent portfolios to create sustainable competitive advantages, and connecting them with a base of high-quality investors with deep technology expertise. For more information, please visit www.mdb.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements”. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed registration statement on Form S-1. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

(RNN) to Present Data on RX-3117 and RX-21101

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center.

The first poster entitled, “A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine,” will be presented on Sunday, April 6, 2014, during the “Experimental and Molecular Therapeutics 6” poster session from 1:00 pm – 5:00 pm in Hall A-E, Poster Section 34. The second poster entitled, “Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy,” for RX-21101 will be presented on Tuesday, April 8, 2014, during the “Chemistry 8” poster session from 1:00 pm – 5:00 pm in Hall A-E, Poster Section 27.

Peter D. Suzdak, Ph.D., CEO of Rexahn, commented, “The inhibition of tumor growth produced by RX-3117 in human cancer cells already resistant to gemcitabine is a very important finding. Approximately 25% of patients treated with gemcitabine become resistant after one cycle of therapy, representing a large unmet medical need and a significant opportunity for the clinical development and potential commercialization of RX-3117.” Rexahn initiated a Phase Ib clinical trial of RX-3117 in cancer patients with solid tumors in January 2014.

RX-21101 is the first development candidate derived from the Company’s Nano-Polymer-Drug Conjugate Systems (NPDCS) platform. This technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. RX-21101 is a polymer conjugated form of docetaxel, a common chemotherapy agent that is now generic but is marketed worldwide under the trade name Taxotere® and had annual sales of $3.1 billion when still under patent.

“In preclinical studies, RX-21101 has demonstrated increased efficacy and reduced toxicity, as compared to intravenously administered free docetaxel,” explained Dr. Suzdak. “RX-21101 contains a signaling moiety that directs the delivery of docetaxel into tumor cells while minimizing the free circulating levels of docetaxel. This approach reduces potential adverse events and maximizes the anti-tumor activity of docetaxel.”

“The NPDCS platform has the potential to generate multiple development candidates using other pharmaceutical companies’ cytotoxic anticancer compounds, transforming them into cancer cell specific compounds with reduced side effects and increased efficacy. This represents a clinical development approach for Rexahn with lower risk, using FDA approved anticancer compounds. Rexahn looks forward to utilizing the NPDCS platform to develop multiple development candidates for either internal development or out licensing,” Dr. Suzdak concluded.

About RX-3117

RX-3117 is a next generation nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase (UCK) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK is overexpressed in multiple human tumors, but has a limited presence in normal tissues. This unique specificity for cancer cells may lead to an improved efficacy and safety profile in cancer patients. RX-3117 also mediates the downregulation of DNA methyltransferase 1 (DNMT1), an enzyme responsible for the methylation of cytosine residues on newly synthesized DNA and also a target for anticancer therapies. Preclinical studies have shown RX-3117 to be effective in both inhibiting the growth of various human cancer xenograft models, including colon, lung, renal and pancreas, as well as overcoming chemotherapeutic drug resistance.

RX-3117 has demonstrated a broad spectrum anti-tumor activity against 50 different human cancer cell lines and efficacy in 12 different mouse xenograft models. The efficacy in the mouse xenograft models was superior to that of gemcitabine. In addition, RX-3117 still retains its full anti-tumor activity in human cancer cell lines made resistant to the anti-tumor effects of gemcitabine. In August 2012, Rexahn reported the completion of an exploratory Phase I clinical trial of RX-3117 in cancer patients conducted in Europe, to investigate the oral bioavailability, safety and tolerability of the compound. In this study, oral administration of RX-3117 demonstrated an oral bioavailability of 56% and a plasma half-life (T_1/2) of 14 hours. In addition, RX-3117 was safe and well tolerated in all subjects throughout the dose range tested.

About RX-21101

RX-21101 was developed using the Nano-Polymer-Drug Conjugate Systems (NPDCS) platform jointly discovered with the University of Maryland at Baltimore. This technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. The direct delivery of chemotherapeutic drugs into the tumors has been shown to result in increased efficacy and reduced toxicity. The NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling moiety which directs the drug into the tumor. This approach minimizes the levels of freely circulating anti-cancer agents in the body, which can dramatically reduce potential adverse events, and maximizes anti-tumor activity by accumulating in the cancer tumor. NPDCS is a broad platform that has the potential to generate multiple therapeutic candidates going forward.

RX-21101 (HPMA-docetaxel-folate) is a polymer conjugated form of docetaxel, a common chemotherapy agent. In preclinical studies, RX-21101 demonstrated increased efficacy and reduced toxicity, as compared to intravenously administered free docetaxel. Docetaxel is now generic but is marketed worldwide under the trade name Taxotere® for the treatment of breast, ovarian, prostate, and non-small cell lung cancer. Despite its commercial success, docetaxel is toxic to all dividing cells in the body and is associated with a high incidence of adverse events including anemia, infection, fever, neutropenia, neuropathy, asthenia, edema, alopecia, nausea and vomiting. These adverse events are the result of high concentrations of free docetaxel in the blood. By minimizing the circulating concentration of free docetaxel in the blood and maximizing the concentration in the cancer tumor, RX-21101 may increase anti-tumor activity and a lower incidence of adverse events.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin^®, RX-3117, and Supinoxin^TM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

(ATTU) Announces New Big Data Management Platform

Attunity Maestro puts control at users’ fingertips to increase business productivity and improve IT efficiencies across global data centers or in the cloud

BURLINGTON, Massachusetts, April 2, 2014 /PRNewswire/ —

Attunity Ltd. (NASDAQ CM: ATTU), a leading provider of information availability software solutions, today announced the release of Attunity Maestro, a new and innovative Big Data management platform designed to help organizations automate the complex process of composing, conducting and monitoring information flow across the entire global enterprise – easily and efficiently. The solution is expected to enable organizations to increase business productivity by empowering them to design and monitor large Big Data transfer processes using its powerful, unified control platform.

“Mapping, executing and managing the flow of data between a myriad heterogeneous systems – both analytical and operational/transactional systems – are critical functions for enterprises that want to become truly data-driven,” said Jeffrey Kelly, Principal Research Contributor and lead Big Data Analyst at Wikibon, a leading open source IT research community focused on infrastructure, Big Data, cloud and software-led innovations. “Attunity Maestro is designed to simplify these otherwise complex functions so that enterprises can deliver the right data to the right system at the right time.”

Supporting global data centers and cloud environments, Attunity Maestro is engineered for medium to large enterprises that need to integrate critical data transfer processes into daily business activity. The solution accelerates and coordinates data transmission and deployment processes of Big Data and large-file assets, delivering speed, simplicity and scalability to virtually any business or IT processes that require information availability.

Designed to meet the needs of a diverse portfolio of users: IT Operations, Lines of Business and Risk Management Teams alike, Attunity Maestro provides unique controls for defining, executing, managing and auditing all transaction and automation initiatives. Common uses will include data distribution to remote location(s), data consolidation for central analytics, enterprise-wide content management and sharing, and multi-stage content deployment.

Using Attunity Maestro, organizations can:

• Centrally manage and control information flow processes
• Enjoy and benefit from quick time-to-value
• Enable higher efficiency and productivity
• Empower line-of-business staff to self-service
• Free up IT resources

For more details about Attunity Maestro, visit http://www.attunity.com/products/attunity-maestro.

“Global organizations implementing Big Data initiatives are increasingly challenged with managing and monitoring their most precious and fastest growing asset – their data,” explained Shimon Alon, Chairman and CEO at Attunity. “With Attunity Maestro, we are pleased to address this critical need head-on and help organizations to better manage the flow of information throughout their globally-distributed enterprises. We believe that Attunity Maestro will become a strategic driver for our future growth and expand our addressable markets, immediately providing us with a competitive advantage.”

Tweet This:
Attunity Announces New #BigData Mgmt Platform for Conducting/Monitoring Info Flow Across Global Enterprises http://bit.ly/1kq3Afx #Maestro

About Attunity

Attunity is a leading provider of information availability software solutions that enable access, management, sharing and distribution of data, including Big Data, across heterogeneous enterprise platforms, organizations, and the cloud. Our software solutions include data replication, data management, change data capture (CDC), data connectivity, enterprise file replication (EFR), managed-file-transfer (MFT), and cloud data delivery. Using Attunity’s software solutions, our customers enjoy significant business benefits by enabling real-time access and availability of data and files where and when needed, across the maze of heterogeneous systems making up today’s IT environment.

Attunity has supplied innovative software solutions to its enterprise-class customers for nearly 20 years and has successful deployments at thousands of organizations worldwide. Attunity provides software directly and indirectly through a number of partners such as Microsoft, Oracle, IBM and HP. Headquartered in Boston, Attunity serves its customers via offices in North America, Europe, and Asia Pacific and through a network of local partners. For more information, visit http://www.attunity.com or our In Tune blog and join our community on Twitter, Facebook, LinkedIn and YouTube, the content of which is not part of this press release.

SafeHarbor Statement

This press release contains forward-looking statements, including statements regarding the anticipated features and benefits of Replicate Solutions, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal Securities laws. Statements preceded by, followed by, or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. For example, when we say that we expect Attunity Maestro to be a strong driver of our future growth, we use a forward-looking statement. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results, expressed or implied by such forward-looking statements, could differ materially from Attunity’s current expectations. Factors that could cause or contribute to such differences include, but are not limited to: our reliance on strategic relationships with our distributors, OEM and VAR partners, and on our other significant customers; risks and uncertainties relating to acquisitions, including costs and difficulties related to integration of acquired businesses; timely availability and customer acceptance of Attunity’s new and existing products, including Attunity Maestro; changes in the competitive landscape, including new competitors or the impact of competitive pricing and products; a shift in demand for products such as Attunity’s products; the impact on revenues of economic and political uncertainties and weaknesses in various regions of the world, including the commencement or escalation of hostilities or acts of terrorism; and other factors and risks on which Attunity may have little or no control. This list is intended to identify only certain of the principal factors that could cause actual results to differ. For a more detailed description of the risks and uncertainties affecting Attunity, reference is made to Attunity’s latest Annual Report on Form 20-F which is on file with the Securities and Exchange Commission (SEC) and the other risk factors discussed from time to time by Attunity in reports filed with, or furnished to, the SEC. Except as otherwise required by law, Attunity undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

© Attunity 2014. All Rights Reserved. Attunity is a registered trademark of Attunity Inc. All other product and company names herein may be trademarks of their respective owners.

Press contacts:

Melissa Kolodziej, Director of Marketing Communications, Attunity
melissa.kolodziej@attunity.com
Tel. +1-781-730-4073

(SNBC) Agrees To Hire Thomas M. O’Brien As President And Chief Executive Officer

VINELAND, N.J., April 2, 2014 — Sun Bancorp, Inc. (NASDAQ: SNBC) (the “Company”) announced today that the Company and its wholly owned subsidiary, Sun National Bank (the “Bank”), have agreed to hire Thomas M. O’Brien as the President and Chief Executive Officer of the Company and the Bank, subject to prior receipt of regulatory non-objection from the Federal Reserve Board and the Office of the Comptroller of the Currency.  Mr. O’Brien will serve as a consultant to the Board of Directors of the Bank and will not assume the duties and responsibilities of President and CEO until such regulatory non-objections are received.  Sidney R. Brown, Chairman of the Board of the Company, will continue to serve as Interim President and Chief Executive Officer until the time Mr. O’Brien becomes an employee.

Mr. O’Brien is an accomplished leader in the financial services industry with over 37 years of industry experience.  He has served on the board of BankUnited, Inc. since May 2012 and has extensive knowledge of the banking industry in the Northeastern U.S. Mr. O’Brien served as President and Chief Executive Officer of State Bank of Long Island/State Bancorp, Inc. from November 2006 to January 2012.  From 2000 to 2006, Mr. O’Brien was President and Chief Executive Officer of Atlantic Bank of NY and, following the acquisition of Atlantic Bank of NY by New York Commercial Bank, continued to serve as President and Chief Executive Officer during the post-closing transition.  From 1996 to 2000, Mr. O’Brien was Vice Chairman and a board member of North Fork Bank and North Fork Bancorporation, Inc.  From 1977 to 1996, Mr. O’Brien was Chairman, President and Chief Executive Officer of North Side Savings Bank.

Recognized as an industry thought leader, Mr. O’Brien served as a director of the Federal Home Loan Bank of New York from 2008 to 2012 and served as Chairman of NY Bankers Association in 2007.  He is currently Trustee and Chairman of the Audit Committee of Prudential Insurance Company of America $175 Billion Annuity Fund Complex, Vice-Chairman of the board and Chairman of the Finance Committee of Archcare and Catholic Healthcare Foundation for the Archdiocese of New York.

“We are pleased to have Tom O’Brien join us.  We expect he will be an effective catalyst to help complete the implementation of our ongoing regulatory compliance program, improve our regulatory standing and advance our growth as one of the largest commercial banking organizations in New Jersey,” said Brown. “We believe Tom O’Brien’s leadership will help us turn the corner, move forward, and begin to lay the foundation for a new era of operational stability, growth and profitability for our shareholders,” said Brown.

In commenting on his appointment, Mr. O’Brien stated “I look forward to joining Sun and believe that the opportunity for its prosperity has never been greater.  Sun enjoys the benefits of both scale and agility.  I believe that with an intense focus on finishing the remaining corrective initiatives to bring about the conclusion of the currently outstanding regulatory agreement, that Sun is very well positioned to succeed in the years ahead.  Initially, I will focus on comprehensively addressing these regulatory matters and thereafter begin to identify and build those businesses that represent the bank’s core competencies so that Sun can continue on its path toward sustainable profits and growth.  We will deliver on Sun’s potential for a strong regulatory compliance culture, stable earnings, strong asset quality and superior customer satisfaction.   As the management team works together with a vibrant and committed board of directors, Sun will be poised to set new standards for earnings consistency, operating efficiency and growth.”

“I will not only be joining Sun as its CEO but, more importantly, I will be joining as a significant shareholder.  As a consequence, my interests will be closely aligned with the long term interests of all shareholders and my ambition will be to build the value for them that they so richly deserve.”

Sun Bancorp, Inc. (NASDAQ: SNBC) is a $3.1 billion asset bank holding company headquartered in Vineland, New Jersey, with its executive offices located in Mt. Laurel, New Jersey. Its primary subsidiary is Sun National Bank, a full service commercial bank serving customers through 50-plus locations in New Jersey. Sun National Bank is an Equal Housing Lender and its deposits are insured up to the legal maximum by the Federal Deposit Insurance Corporation (FDIC). For more information about Sun National Bank and Sun Bancorp, Inc., visit www.sunnationalbank.com.

Cautionary Note Regarding Forward-Looking Statements

The foregoing material contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, concerning the financial condition, results of operations and business of the Company.  Forward-looking statements are statements that include projections, predictions, expectations or beliefs about events or results or otherwise are not statements of historical facts, including statements about completing the implementation of our ongoing regulatory compliance program, improving our regulatory standing, encouraging our growth as one of the largest commercial banking organizations in New Jersey, addressing the regulatory and other challenges facing the Bank and laying the foundation for a new era of operational stability, growth and profitability for our shareholders.  Actual results and trends could differ materially from those set forth in such statements and there can be no assurances that we will complete the implementation of our ongoing regulatory compliance program, improve our regulatory standing, grow as one of the largest commercial banking organizations in New Jersey, effectively address the regulatory and other challenges facing the Bank or lay the foundation for a new era of operational stability, growth and profitability for our shareholders.  We caution that such statements are subject to a number of uncertainties, including those detailed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K for the fiscal year ended December 31, 2013 and in other filings made pursuant to the Securities Exchange Act of 1934, as amended.  Therefore, readers should not place undue reliance on any forward-looking statements.  The Company does not undertake, and specifically disclaims, any obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

(VISN) to Hold Extraordinary General Meeting of Shareholders on April 24, 2014

BEIJING, April 2, 2014  — VisionChina Media Inc. (“VisionChina” or “the Company”) (Nasdaq: VISN), one of China’s largest out-of-home digital television advertising networks on mass transportation systems, today announced it will hold an extraordinary general meeting of shareholders at the offices of Simpson Thacher & Bartlett, 35/F ICBC Tower, 3 Garden Road, Central, Hong Kong, Hong Kong S.A.R., at 9:30 a.m. Beijing / Hong Kong time on April 24, 2014 (9:30 p.m. ET on April 23, 2014). The Company has fixed the close of business on April 3, 2014 as the record date for the determination of shareholders entitled to notice of, and to vote at, the extraordinary general meeting of shareholders.

The notice of the extraordinary general meeting of shareholders and the proxy statement related to the meeting are available through the investor relations section of the Company’s website.

About VisionChina Media Inc.

VisionChina Media Inc. (Nasdaq: VISN) operates an out-of-home advertising network on mass transportation systems, including buses and subways. As of December 31, 2013, VisionChina Media’s advertising network included 111,163 digital television displays on mass transportation systems in 19 of China’s economically prosperous cities, including Beijing, Guangzhou, and Shenzhen, as secured by exclusive agency agreements or joint venture contract. VisionChina Media has the ability to deliver real-time, location-specific broadcasting, including news, stock quotes, weather and traffic reports, and other entertainment programming. For more information, please visit http://www.visionchina.cn.

For investor and media inquiries, please contact:

In China:

Ms. Shuning Yi
Investor Relations Department
VisionChina Media Inc.
Tel: +86-134-2090-9426
Email: shuning.yi@visionchina.cn

Mr. Colin Wang
Investor Relations Director
VisionChina Media Inc.
Tel: +86-135-1001-0107
Email: colin.wang@visionchina.cn

In the United States:

Mr. Justin Knapp
Ogilvy Financial, U.S.
Tel: +1-616-551-9714
E-mail: visn@ogilvy.com

(VNRX) President and CEO of VolitionRx Issues Corporate Update

Company Also Releases New Corporate Videos to YouTube Channel

(ISRG) Announces New da Vinci® Xi™ Surgical System

SUNNYVALE, Calif., April 1, 2014  — Intuitive Surgical, Inc. (Nasdaq:ISRG), the global leader in robotic-assisted minimally invasive surgery, today announced the FDA clearance and U.S. introduction of the da Vinci Xi Surgical System, a technological leap forward in replacing large-incision abdominal surgeries (open surgery) with a minimally invasive approach.

The da Vinci Xi System has broader capabilities than prior generations of the da Vinci System. It can be used across a wide spectrum of minimally invasive surgical procedures and has been optimized for complex, multi-quadrant surgeries.

For more than a decade, da Vinci Surgical Systems have provided patients with a minimally invasive alternative to open surgery that reduces many of the costs and complications associated with open procedures. Intuitive Surgical designed the new da Vinci Xi System with the goal of further advancing the technology used in minimally invasive surgery for complex diseases and conditions in gynecology, urology, thoracic, cardiac, and general surgery.

“Our goal is to develop technology that enhances surgical performance,” said Gary Guthart, Intuitive Surgical President and Chief Executive Officer. “The da Vinci Xi System’s new overhead architecture means that multi-quadrant surgery can be performed without repositioning the system, an innovation long sought by surgeons who perform complex procedures. We strive to provide the most advanced, least invasive option for surgery, and we are working hard to make minimally invasive surgery the standard of care.”

With the U.S. introduction now underway, Intuitive Surgical will be seeking regulatory clearances to market the da Vinci Xi System around the world.

Efficient Anatomical Access, Crystal Clear 3D-HD Visualization

By enabling efficient access throughout the abdomen and chest, the da Vinci Xi System expands upon core da Vinci System features, including wristed instruments, 3D-HD visualization, intuitive motion, and an ergonomic design. As with all da Vinci Surgical Systems, the da Vinci Xi System’s immersive 3D-HD vision system provides surgeons a highly magnified view, virtually extending their eyes and hands into the patient.

Compared to prior da Vinci Systems, the da Vinci Xi System’s key features include:

• A new overhead instrument arm architecture designed to facilitate anatomical access from virtually any position.
• A new endoscope digital architecture that creates a simpler, more compact design with improved visual definition and clarity.
• An ability to attach the endoscope to any arm, providing flexibility for visualizing the surgical site.
• Smaller, thinner arms with newly designed joints that offer a greater range of motion than ever before.
• Longer instrument shafts designed to give surgeons greater operative reach.

In addition, the da Vinci Xi System is built to be compatible with Intuitive Surgical’s Firefly™ Fluorescence Imaging System. While it is not currently available, we plan to seek regulatory clearance for use of Firefly Imaging with the da Vinci Xi System. This technology is currently available as an option with the da Vinci Si™ model, and it is used to provide the surgeon with additional visual information in a variety of surgical procedures by enabling real-time visualization and assessment of vessels, bile ducts and tissue perfusion.

A System Designed For the Future

The da Vinci Xi System is an expandable technology platform that is designed to accommodate and seamlessly integrate a range of current technologies in areas such as imaging, advanced instruments and anatomical access, as well as future innovations.

To provide hospitals with choices to match their needs, Intuitive Surgical will continue to offer the current da Vinci Si System, which addresses a broad span of procedure complexity, and the da Vinci Si-e™ System, a lower-cost system suited for less complex surgeries.

For more information about the da Vinci Xi Surgical System, visit intuitivesurgical.com.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the global leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the da Vinci^® Surgical System. Intuitive Surgical’s mission is to extend the benefits of minimally invasive surgery to those patients who can and should benefit from it.

About the da Vinci Surgical System

The da Vinci Surgical System is a surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci Surgical System consists of an ergonomic surgeon console or consoles, a patient-side cart with three or four interactive arms, a high-performance vision system and proprietary EndoWrist^® instruments. Powered by state-of-the-art technology, the da Vinci Surgical System is designed to scale, filter and seamlessly translate the surgeon’s hand movements into more precise movements of the EndoWrist instruments. The net result is an intuitive interface with advanced surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort compared to other surgical approaches, the da Vinci Surgical System makes it possible for skilled surgeons to perform minimally invasive procedures involving complex dissection or reconstruction.

All surgery presents risk, including da Vinci Surgery and other minimally invasive procedures. Serious complications may occur in any surgery, up to and including death. Examples of serious and life-threatening complications, which may require hospitalization, include injury to tissues or organs, bleeding, infection, and internal scarring that can cause long-lasting dysfunction or pain. For more complete information on risks, considerations, safety, and indications for use, please refer to www.davincisurgery.com. For more information about clinical evidence related to da Vinci Surgery, please visit www.intuitivesurgical.com/company/clinical-evidence/.

Indications for Use for the da Vinci^® Xi™ Surgical System

The Intuitive Surgical Endoscopic Instrument Control System (da Vinci Surgical System, Model IS4000) is intended to assist in the accurate control of Intuitive Surgical Endoscopic Instruments including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, scalpels, forceps/pick-ups, needle holders, endoscopic retractors, electrocautery and accessories for endoscopic manipulation of tissue, including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrocautery, suturing, and delivery and placement of microwave and cryogenic ablation probes and accessories, during urologic surgical procedures, general laparoscopic surgical procedures, gynecologic laparoscopic surgical procedures, general thoracoscopic surgical procedures and thoracoscopically assisted cardiotomy procedures. The system can also be employed with adjunctive mediastinotomy to perform coronary anastomosis during cardiac revascularization. The system is indicated for adult and pediatric use. It is intended to be used by trained physicians in an operating room environment in accordance with the representative, specific procedures set forth in the Professional Instructions for Use.

Indications for use for Firefly™ Fluorescence Imaging for the da Vinci Si Surgical System

The da Vinci^® Fluorescence Imaging Vision System (Firefly™ Fluorescence Imaging) is intended to provide real-time endoscopic visible and near-infrared fluorescence imaging. The da Vinci Fluorescence Imaging Vision System enables surgeons to perform minimally invasive surgery using standard endoscopic visible light as well as visual assessment of vessels, blood flow and related tissue perfusion, and at least one of the major extra-hepatic bile ducts (cystic duct, common bile duct, and common hepatic duct) using near infrared imaging.

Fluorescence imaging of biliary ducts with the da Vinci Fluorescence Imaging Vision System is intended for adjunctive use only in conjunction with standard of care white light and, when indicated, intraoperative cholangiography. The device is not intended for standalone use for biliary duct visualization.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding regulatory clearances to market the da Vinci Xi System around the world. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including those under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2013, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

CONTACT: Intuitive Surgical Corporate Communications
         408-523-7337
         corpcomm@intusurg.com

(CSUN) Builds Strategic Partnership with Larsen & Toubro

NANJING, China, April 1, 2014  — China Sunergy Co., Ltd. (NASDAQ: CSUN) (“China Sunergy” or “the Company”), a specialized solar cell and module manufacturer, today announced that the Company had completed totaled 29.5MW solar modules shipment under two separate supply agreements to Larsen & Toubro Limited (“Larsen & Toubro”), an Indian conglomerate and solar developer headquartered in Chennai, India. China Sunergy has officially advanced into Larsen & Toubro’s strategic suppliers list in solar business.

Larsen & Toubro is one of India’s leading industry conglomerates in technology, engineering, construction, and manufacturing. In solar sector, Larsen & Toubro has solidified its leading position with over 300 MW solar projects executed / under-execution so far in Indian market.

China Sunergy’s high efficient multi-crystalline modules will be deployed in two large-scale projects, including a large scale roof-top project with installation capacity of 7.5MW and 22MW ground-mounted solar projects.

Mr. Stephen Cai, CEO of China Sunergy, remarked, “With natural geographic advantages and government support, India is destined to become one of the world’s largest and most dynamic markets. We are delighted to be a strategic supplier to Larsen & Toubro and we believe that Larsen & Toubro’s outstanding market presence in India and China Sunergy’s reliable & advanced products should benefit both of us mutually and place in an excellent position to capture a greater market share in India.”

About China Sunergy Co., Ltd.

China Sunergy Co., Ltd. (NASDAQ:CSUN) designs, manufactures and delivers high efficiency solar cells and modules to the world from its production centers based in China and Turkey. China Sunergy also invests in high potential solar projects. Founded in 2004, China Sunergy is well known for its advanced solar cell technology, reliable product quality, and excellent customer service.

For more information, please visit http://www.csun-solar.com.

Investor and Media Contacts:

Safe Harbor Statement

This announcement may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements. These forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company and the industry, and involve known and unknown risks and uncertainties, including but not limited to, the Company’s failure to maintain its listing qualification due to, among other things, volatility in the Company’s ADS price; the Company’s ability to raise additional capital or renew existing bank borrowings as they become due to finance the Company’s activities; the Company’s customers’ financial condition and creditworthiness, and their ability to settle accounts receivables; the effectiveness, profitability, and the marketability of its products; litigations and other legal proceedings, including any decisions by the US International Trade Committee and Department of Commerce on the petitions filed; the economic slowdown in China and elsewhere and its impact on the Company’s operations; demand for and selling prices of the Company’s products, execution of our strategy to expand into downstream solar power businesses, the future trading of the common stock of the Company; the ability of the Company to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; the Company’s ability to protect its proprietary information; general economic and business conditions; the volatility of the Company’s operating results and financial condition; the Company’s ability to attract or retain qualified senior management personnel and research and development staff; future shortage or availability of the supply of raw materials; impact on cost-competitiveness as a result of entering into long-term arrangements with raw material suppliers and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

(DRRX) Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations

CUPERTINO, Calif., April 1, 2014  — DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR^™ (SABER^®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39^th Annual American Society of Regional Anesthetic and Pain Medicine Meeting.  The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago.

(ISR) Announces Five Presentations at the American Brachytherapy Society Convention

Oral Presentations and Posters on Various Studies Utilizing Cesium-131 Will Be at Center Stage

(ENVI) Powers Premium Live Video Service Delivered to Apple TV

SOUTH SAN FRANCISCO, Calif., April 1, 2014  — Envivio (Nasdaq:ENVI), a leading provider of software-based video processing and delivery solutions, today announced that it is powering premium live HD sports channels on Apple TV for a European Tier 1 service provider.

The premium channels are compressed using Envivio Muse™ Live encoders, protected using a new encryption mode by Envivio Halo™ network media processors (NMP) and delivered to Apple TV. Envivio showcased the live service at the recent TV Connect exhibition in London.

Halo is designed to support live or on-demand adaptive bitrate TV for the full range of Apple devices, using the latest content protection technologies. This capability is critical for video operators desiring to securely deliver high quality premium content to Internet-connected devices.

“We are the leaders in adaptive bitrate compression and video processing innovations for Internet and over-the-top TV, and continue to enhance our solutions by providing support for a broad range of devices and formats, including Apple TV and the related content protection technologies,” said Julien Signès, Envivio’s president and CEO.

The Envivio Halo NMP is designed to provide a wide range of advanced video processing functions for any-screen services, including packaging, encryption and distribution. Halo also supports time-shifted TV applications such as multi-screen network PVR, Catch-up and Start-over TV with live-to-file capabilities, targeted ad insertion, and personalized content creation in the network.

Installed centrally or distributed in the network, Halo offers huge network capacity savings and increases the flexibility of multi-screen operations. Halo NMPs use existing broadcast infrastructure to efficiently deliver advanced, secure video services for the latest smartphones, tablets, connected TVs, game consoles and PCs.

More than 300 content and service providers around the globe have selected Envivio to power their multi-screen and pay TV services. Visit www.envivio.com to learn more about TV without boundaries.

About Envivio

Envivio (Nasdaq:ENVI) is the leader in software-based video processing and delivery solutions for any screen, with over 300 content and service provider customers worldwide. Envivio solutions remove the boundaries of traditional television and enable operators to increase their revenues, by providing viewers with best-in-class video quality and a compelling, personalized experience. Envivio is headquartered in South San Francisco, California and has offices worldwide including France, England, China, Singapore and Japan. Visit www.envivio.com for more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the anticipated benefits and features of Envivio’s products. Actual results may vary materially due to a number of factors including, but not limited to, the risk that, capital spending in our target markets decreases or is delayed, we are unable to maintain profitability, our relationship with our channel partners is disrupted, as well as other risks that are detailed from time to time in Envivio’s SEC reports, which can be found at www.sec.gov. Envivio is under no obligation to (and expressly disclaims any such obligation to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. Information contained in our website is not incorporated by reference in, or made part of this press release.

Editor’s Note: All trademarks used herein, whether recognized or not, are the properties of their respective companies.

CONTACT: Envivio
         Sarah Lum
         pr@envivio.com
         +1.650.243.2710

         The Blueshirt Group
         Investor Relations for Envivio
         Cynthia Hiponia or Alice Kousoum
         ir@envivio.com
         +1.650.243.2702

(TLOG) Announces Publication of Preclinical Characterization of Birinapant

MALVERN, Pa., April 1, 2014  — TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.

The publication titled “Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-{kappa}B Activation, and Is Active in Patient-Derived Xenograft Models,” will appear in the April edition of Molecular Cancer Therapeutics. The electronic version of the publication is available online at http://mct.aacrjournals.org/content/early/2014/03/24/1535-7163.MCT-13-0798.abstract.

The experiments described in the publication demonstrate that birinapant bound to the BIR3 domains of cIAP1, cIAP2, XIAP, and the BIR domain of ML-IAP in vitro and induced the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2, resulting in induction of tumor cell death. Birinapant preferentially targeted the TRAF2-associated cIAP1 and cIAP2 with subsequent inhibition of TNF-induced NF-{kappa}B activation. The activity of a variety of chemotherapeutic cancer drugs was potentiated by birinapant, and tumor growth in multiple primary patient–derived xenotransplant models was inhibited by birinapant at well-tolerated doses.

“We are very pleased with the results of these studies, which support the therapeutic combination of birinapant with multiple chemotherapies, particularly with those therapies that can induce TNF secretion,” said C. Glenn Begley, Chief Scientific Officer of TetraLogic. “These data support our belief that birinapant has the potential to be broadly applicable across a variety of cancers.”

About TetraLogic

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic the Second Mitochondrial Activator of Caspases, or SMAC-Mimetics, and are designed to cause or enable abnormal cells that are resistant to the body’s immune system to self-destruct. Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic’s pre-clinical and clinical development of birinapant and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19,2014.

Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: Company Contact:
         Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889-9900, x103
         pete.meyers@tlog.com

         Investor Relations Contact:
         Ami Bavishi
         Burns McClellan, Inc.
         (212) 213-0006
         abavishi@burnsmc.com